American College

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Retrieved on: 
Sunday, April 7, 2024
Health, Sports, Football, Other Health, Other Science, Research, Science, Blood pressure, TTE, FACC, African Americans, Prevalence, Aortic stenosis, National Football League, Patient, Education, Ageing, Journal, History, MD, City, Male, American College, TAVR, EKG, AFL, Interventional cardiology, Alumni association, NFL, National Football League Alumni, Hypertension, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.
  • Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
  • Conducted across eight U.S. cities in cooperation with NFL Alumni Health, a subsidiary of the NFL Alumni Association, HUDDLE was a cross sectional study of NFL alumni and their family members aged 50 years and above.
  • Study participants self-reported their medical histories and participated in heart health education and screenings that included blood pressure, electrocardiogram (EKG) and echocardiogram.

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Sunday, April 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

Retrieved on: 
Sunday, April 7, 2024
Technology, Medical Devices, Surgery, Health Technology, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Diagnosis, TTE, Machine learning, Cardiovascular disease, Coronary artery disease, Pulmonary hypertension, Patient, Heart, Heart failure, American College, Data collection, FDA, CAD

The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.

Key Points: 
  • The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.
  • Timely identification of left ventricular dysfunction plays a pivotal role in effective heart failure management, however, measuring elevated LVEDP currently relies on invasive left heart catheterization.
  • Sc.D., Executive Vice President and Chief Scientific Officer, CorVista Health.
  • “We believe the CorVista System can uniquely and effectively address these important unmet needs for people living with cardiovascular disease, especially in rural and underserved populations.”

Renowned NYC Foot Surgeon Dr. Stuart J. Mogul Introduces the Revolutionary Lapiplasty Mini-Incision™ Procedure for Accelerated Healing and Recovery

Retrieved on: 
Tuesday, April 9, 2024
ABC, Self (magazine), The New York Times, Weight-bearing, Patient, WebMD, Treace Medical Concepts, News, American College, Publication, Fox News, Position, Multimedia, ABC News, Dentistry

NEW YORK, April 9, 2024 /PRNewswire-PRWeb/ -- Dr. Stuart J. Mogul, a distinguished foot surgeon based in New York City, is proud to announce the incorporation of the groundbreaking Lapiplasty Mini-Incision™ Procedure into his practice. Developed by Treace Medical Concepts, this innovative surgical technique offers patients faster healing, quicker recovery times, and the ability to bear weight sooner following foot procedures.

Key Points: 
  • Patients requiring foot surgery have long relied on the expertise of esteemed New York Foot Surgeon, Dr. Stuart J.
  • Mogul, a distinguished foot surgeon based in New York City , is proud to announce the incorporation of the groundbreaking Lapiplasty Mini-Incision™ Procedure into his practice.
  • The Lapiplasty Mini-Incision™ Procedure revolutionizes foot surgery by addressing issues related to metatarsal alignment through a streamlined and highly effective approach.
  • Dr. Stuart Mogul is a diplomate of The American Board of Foot & Ankle Surgery and fellow of the American College of Foot and Ankle Surgeons.

Oshi Health Is Named a Top Innovator by Modern Healthcare

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Organization, Oshi, Partnership, Patient, GI, American Telemedicine Association, ATA, American College of Gastroenterology, American College, Health, IHI, Gastroenterology, Nursing

NEW YORK, April 9, 2024 /PRNewswire-PRWeb/ -- Oshi Health today announced that it has been named a winner in Modern Healthcare's 2024 Innovators Awards, honored for driving payment innovation in specialty care through its landmark value-based care agreement with Aetna. By building a care model around patient-reported quality measures for gastroenterology, Oshi has paved the way towards revolutionizing digestive health while also modeling the future of accountability and care delivery models in patient care more broadly.

Key Points: 
  • "Oshi Health is proving that everyone can win through new care models that shift dollars to preventive versus sick care, creating a virtuous flywheel effect that empowers clinicians, achieves better outcomes, relieves overwhelmed health systems, and delivers savings," said Sam Holliday, Oshi's CEO.
  • Oshi was the only virtual care company and one of only 10 healthcare organizations in the country to receive this recognition for developing and leading transformative innovations that are driving change across the healthcare industry.
  • "We are honored to be included in this year's class of Modern Healthcare Innovators," said Sam Holliday, Oshi Health CEO.
  • As a virtual center of excellence for gastrointestinal (GI) conditions, Oshi Health provides total care for digestive health, delivering high-touch multidisciplinary care virtually.

enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development

Retrieved on: 
Tuesday, April 9, 2024
NMIBC, BCG, American Urological Association, Master, Professor, Advisory Council, Patient, SVP, Thesis, University, Drug, Society, American College, LEGEND, Bladder cancer, Hofstra University, FACS, Stanford University, AUA, Prostate, Medicine, Pharmaceutical industry

In this role, Dr. Pruthi's responsibilities will include supporting the clinical development of EG-70 across the urologic space, including through engagement with the urological community.

Key Points: 
  • In this role, Dr. Pruthi's responsibilities will include supporting the clinical development of EG-70 across the urologic space, including through engagement with the urological community.
  • He joins enGene from Johnson & Johnson Innovative Medicine, where he was most recently the Global Medical Affairs Leader, Bladder Cancer and Senior Medical Director, Oncology (Global – Prostate and Bladder Cancer).
  • "We are thrilled to welcome Dr. Raj Pruthi to the enGene team.
  • In addition to his position at enGene, Dr. Pruthi maintains multiple prominent leadership roles within the urological community.

Cathie Biga is New American College of Cardiology President

Retrieved on: 
Monday, April 8, 2024
College, FACC, Culture, Practice management, NCDR, Science, Trustee, Knowledge, History, Registry, Health policy, MSN, American College, MPH, Multimedia, ACC, Health, MSCE, Nursing

ATLANTA, April 8, 2024 /PRNewswire/ -- Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization's first non-physician president. She will serve a one-year term representing over 56,000 cardiovascular care team members around the world and leading the cardiovascular organization in its mission to transform cardiovascular care and improve heart health for all.

Key Points: 
  • ATLANTA, April 8, 2024 /PRNewswire/ -- Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization's first non-physician president.
  • "The concept of 'standing on the shoulders of giants' is often referenced when talking about leadership changes and transformation over time.
  • She's been a member of the ACC Board of Trustees for six years, most recently serving as vice president.
  • The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all.

Johnson Pope Welcomes Lauren Taylor to Its Tax Team

Retrieved on: 
Monday, April 8, 2024
Growth, Partnership, Trust, LLP, American College, Lawsuit, The Florida Bar, Estate, Trustee, Partner, Practice, Private law, Multimedia, Property management

TAMPA, Fla., April 8, 2024 /PRNewswire/ -- Johnson, Pope, Bokor, Ruppel & Burns, LLP is pleased to announce that Lauren Taylor has joined the firm as a Partner.

Key Points: 
  • TAMPA, Fla., April 8, 2024 /PRNewswire/ -- Johnson, Pope, Bokor, Ruppel & Burns, LLP is pleased to announce that Lauren Taylor has joined the firm as a Partner.
  • Lauren focuses her practice on complex tax and estate planning, trust and estate administration, and related corporate, partnership, and real estate matters.
  • Established in 1973, Johnson Pope remains committed to delivering the highest quality legal services to our clients.
  • For more information about Johnson Pope Bokor Ruppel & Burns, LLP, and its comprehensive range of legal services, visit https://www.jpfirm.com .

New Clinical Study Reveals Consuming 12 Eggland's Best Eggs Weekly Shows No Negative Effects on Cholesterol Levels; Study Also Suggests Possible Benefits for Some Consumers

Retrieved on: 
Monday, April 8, 2024
Research, Health, LDL, Cardiovascular disease, Vitamin, Nutrient, Cardiology, Diabetes, Risk, Patient, Senior, American College, Clinical trial, HDL, Cholesterol, Egg as food, Duke, Vitamin B12, Pharmaceutical industry

CEDAR KNOLLS, N.J., April 8, 2024 /PRNewswire/ -- Americans are increasingly aware of the impact of cholesterol on heart health and well-being, but for decades, there have been conflicting headlines about which foods can have positive or negative effects. Eggs, in particular, have often received negative press related to cholesterol. However, a new study presented at the American College of Cardiology's Annual Scientific Session that was led by researchers at Duke and sponsored by Eggland's Best, offers promising new evidence on fortified eggs.

Key Points: 
  • The clinical trial studied 140 participants from a broadly generalized population who had a high risk of heart disease.
  • Researchers randomized participants into two groups, asking half to eat two or fewer eggs per week for four months.
  • Ultimately, the study found that over 4 months, eating Eggland's Best eggs resulted in no adverse effects on lipid profiles and markers of cardiovascular risk for these patients.
  • The consumption of Eggland's Best eggs may also increase Vitamin B12 levels, also helping to support a healthier lifestyle.